To determine the connection between REGγ expression and clinical outcomes in cancers with KRAS mutations, we examined REGγ expression in human colon cancer tissues, including the KRAS-MUT subgroup (n = 10) and the KRAS-WT subgroup (n = 14). This evidence concerns the gene KRAS and malignant colon neoplasm.